VIENNA—Three key targetable pathways for breast cancer treatment were assessed at the St Gallen Breast Cancer Conference by Clifford Hudis, MD, Chief of the Breast Medicine Service at Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York. He gave Oncology Times reporter Sarah Maxwell his review of the clinical usefulness of targeting the CDK 4-6, PIK3CA and FGFR pathways.
You may also like...
Deep Genomic Profiling in Breast Cancer Promises to Improve Outcomes 26 Mar, 2015 ALK—Targeted Lung Cancer Drugs Benefited Real World Patients 7 Nov, 2018 Polygenic Risk Scores Could Help Predict Second Primary Breast Cancers—AUDIO JOURNAL OF ONCOLOGY 28 Mar, 2018 ‘Rescanning’ Optimizes Pencil Beam Proton Delivery to Moving Lung Tumor 12 May, 2015
- Previous story Breast Cancer Prognostic Implications of Obesity and Insulin Resistance
- Next story No Prime Time Soon for Vaccines in Lung Cancer—Immune Suppression Reversal Urgently Needed
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014